Insider Selling: Artivion (NYSE:AORT) EVP Sells $160,069.65 in Stock

Artivion, Inc. (NYSE:AORT) EVP Lance Berry sold 4,485 shares of the company’s stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $35.69, for a total value of $160,069.65. Following the completion of the sale, the executive vice president owned 143,965 shares of the company’s stock, valued at $5,138,110.85. This trade represents a 3.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Artivion Price Performance

Shares of NYSE AORT opened at $38.52 on Friday. Artivion, Inc. has a twelve month low of $21.97 and a twelve month high of $48.25. The company has a current ratio of 3.53, a quick ratio of 2.62 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $1.84 billion, a price-to-earnings ratio of 192.58 and a beta of 1.59. The firm has a 50-day moving average of $41.93 and a two-hundred day moving average of $43.02.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The business had revenue of $118.30 million during the quarter, compared to analyst estimates of $116.42 million. Artivion’s quarterly revenue was up 19.2% on a year-over-year basis. As a group, analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Artivion

Hedge funds have recently bought and sold shares of the company. Royal Bank of Canada boosted its holdings in Artivion by 107.0% in the 1st quarter. Royal Bank of Canada now owns 38,707 shares of the company’s stock valued at $952,000 after purchasing an additional 20,010 shares during the period. AQR Capital Management LLC increased its holdings in shares of Artivion by 8.8% during the 1st quarter. AQR Capital Management LLC now owns 35,053 shares of the company’s stock worth $862,000 after purchasing an additional 2,823 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Artivion by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company’s stock valued at $580,000 after buying an additional 1,032 shares during the last quarter. Oppenheimer Asset Management Inc. acquired a new position in shares of Artivion during the second quarter valued at about $669,000. Finally, Envestnet Asset Management Inc. lifted its stake in shares of Artivion by 364.4% in the second quarter. Envestnet Asset Management Inc. now owns 52,871 shares of the company’s stock valued at $1,644,000 after buying an additional 41,487 shares during the period. 86.37% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have weighed in on AORT shares. Weiss Ratings upgraded shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Oppenheimer restated an “outperform” rating and set a $50.00 price target on shares of Artivion in a report on Friday, November 7th. Wall Street Zen lowered Artivion from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Needham & Company LLC reissued a “buy” rating and set a $58.00 price objective on shares of Artivion in a research report on Monday, February 2nd. Finally, Canaccord Genuity Group lowered their target price on Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a research note on Friday, February 13th. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $48.97.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.